Clear Point Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Clear Point Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27	Closed	-$403	–	194
2024 Q3	$403	Hold	27	–	–	﹤0.01%	512
2024 Q2	$364	Hold	27	–	–	﹤0.01%	511
2024 Q1	$448	Hold	27	–	–	﹤0.01%	501
2023 Q4	$363	Buy	+27	New	+$295	﹤0.01%	499

Other funds holding CNCR

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clear Point Advisors's CNCR Position: Q4 2024 in Review

Clear Point Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2024, closing a stake of 27 shares — an estimated $403 sold.

Clear Point Advisors first reported a position in CNCR in Q4 2023 and held it in 4 quarters. The position peaked at $448 in Q1 2024. 11 funds tracked by Wall St. Rank hold CNCR as of Q4 2024.

Clear Point Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2024 after selling out during the quarter.
Clear Point Advisors sold 27 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2024, an estimated $403.
Clear Point Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2023 and held it in 4 quarters.
Clear Point Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $448 in Q1 2024.
11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2024.

Based on Clear Point Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.